MS 2019

  1. interferon beta-1A
    • Avonex (IM once weekly)
    • Rebif (SC TIW)
    • Plegridy (pegylated - SC Q14 days)
  2. glatiramer
    • Copaxone
    • Glatopa
    • MOA: MBP decoy
  3. mitoxantrone
    • Novantrone
    • MOA: Cytocidal and DNA-reactive
  4. natalizumab
    • Tysabri
    • MOA: monoclonal antibody alpha4beta1 cell adhesion
  5. alemtuzumab
    • Lemtrada
    • MOA: humanized cytolytic monoclonal IgG1 antibody
  6. fingolimod
    • Gilenya
    • MOA: agonist of sphingosine 1-phosphate - sequester lymphocytes
  7. teriflunomide
    • Aubagio
    • MOA: limit expansion of t/b cells and decrease migration of lymphocyte into CNS
  8. dimethyl fumerate
    • Tecfidera
    • MOA: mostly unclear - covalently modify cysteine residues
  9. cladribine
    • Mavenclad 
    • MOA: impair DNA synthesis for B/T lymphocytes, cytotoxic
  10. ocrelizumab
    • Ocrevus
    • MOA: C20 on B lymphocyte cytolysis
  11. simponimod
    • Mayzent
    • MOA: S1P
Author
VASUpharm14
ID
348829
Card Set
MS 2019
Description
MS 2019 drugs
Updated